The Europe Kirsten Rat Sarcoma (KRAS) market is undergoing a significant transformation as the healthcare sector pivots toward precision oncology. KRAS mutations are among the most common genetic alterations in solid tumors, acting as critical biomarkers for lung, colorectal, and pancreatic cancers. With the European Union’s strong emphasis on genomic research and the "Europe's Beating...